Complete Guide to Growth Hormone Secretagogues: Every GH Peptide Explained
Growth hormone sits at the center of some of the most active areas in peptide research today. It influences body composition, metabolic function, sleep architecture, and tissue repair — which is why compounds that modulate its release have attracted sustained scientific attention for decades. Growth hormone secretagogues (GHS) are a class of compounds that stimulate the body's own pituitary gland to produce and release growth hormone (GH), rather than introducing exogenous GH directly. This distinction matters enormously in research contexts, because working with the body's natural regulatory systems tends to produce more nuanced, physiologically relevant data.
This guide covers the full landscape of GH-related peptides currently used in research: how they work, what the published literature says about them, how they differ from one another, and what researchers should know when designing protocols. Whether you're just beginning to explore this area or looking to deepen your understanding of specific compounds, this is your comprehensive reference.
Mechanism of Action
To understand growth hormone secretagogues, you first need a basic map of the GH axis — the chain of signals that controls GH release.
The process begins in the hypothalamus (a region at the base of the brain that acts as a master regulator of many hormonal systems). The hypothalamus releases two key signaling molecules:
- Growth Hormone-Releasing Hormone (GHRH): A peptide that travels to the anterior pituitary (the front portion of the pituitary gland, a pea-sized structure below the brain) and directly stimulates somatotroph cells there to synthesize and release GH.
- Somatostatin: A counter-regulatory peptide that inhibits GH release, acting as a natural brake on the system.
GH then travels through the bloodstream to the liver and peripheral tissues, stimulating the production of IGF-1 (Insulin-Like Growth Factor 1), which mediates many of GH's downstream effects on tissue growth, cellular repair, and metabolism.
Growth hormone secretagogues work by amplifying this natural system through two primary mechanisms:
GHRH Analogs
Compounds like sermorelin, CJC-1295, and tesamorelin are structural analogs of endogenous GHRH. They bind to the GHRH receptor (GHRH-R) on pituitary somatotrophs and stimulate GH synthesis and secretion. The key research interest here is that these compounds respect the natural pulsatile (meaning rhythmic, wave-like) pattern of GH release, which is considered more physiologically authentic than continuous GH elevation.
Ghrelin Mimetics and GHRPs
Growth Hormone-Releasing Peptides (GHRPs) — including GHRP-2, GHRP-6, ipamorelin, and hexarelin — work through a completely different receptor: the GHS-R1a (Growth Hormone Secretagogue Receptor, type 1a), which is also the receptor for ghrelin, a hormone naturally produced in the stomach. Activation of GHS-R1a stimulates GH release through a pathway distinct from GHRH, and also suppresses somatostatin — effectively releasing both the accelerator and the brake simultaneously.
Research has consistently demonstrated that combining a GHRH analog with a GHRP produces synergistic GH release** — meaning the combined effect is substantially greater than either compound alone. This is the scientific rationale behind combination research protocols.
The Oral Exception: MK-677
MK-677 (ibutamoren) is a non-peptide, orally active GHS-R1a agonist. Unlike the peptides above, it is not broken down in the digestive tract and can be administered orally — a significant practical distinction in research design. It mimics ghrelin's action at the receptor level while offering the convenience of oral bioavailability.
Published Research
Sermorelin
Sermorelin is a synthetic analog of the first 29 amino acids of endogenous GHRH (the full molecule has 44 amino acids). It has the longest research history of any compound in this class, with early studies dating to the 1980s.
Research published by Corpas and colleagues (PMID: 1734252) in The Journal of Clinical Endocrinology & Metabolism examined GHRH administration in older adults and demonstrated that the hypothalamic-pituitary axis retained its capacity to respond to GHRH stimulation even with advancing age — a finding with significant implications for understanding age-related GH decline.
Studies have demonstrated that sermorelin's short half-life (approximately 10–20 minutes) means it produces GH pulses that closely mirror the natural secretory pattern, which researchers consider a meaningful advantage when studying physiological GH dynamics.
CJC-1295 (With and Without DAC)
CJC-1295 is a modified GHRH analog engineered for extended stability. It exists in two research forms:
- CJC-1295 Without DAC (view product): Has a half-life of approximately 30 minutes, producing GH pulses similar to sermorelin but with slightly greater stability.
- CJC-1295 With DAC (view product): Incorporates a Drug Affinity Complex (DAC) — a chemical modification that allows the peptide to bind to albumin (a transport protein in the blood), dramatically extending its half-life to approximately 6–8 days.
A landmark study by Ionescu and Frohman (PMID: 16882764), published in The Journal of Clinical Endocrinology & Metabolism, examined CJC-1295 in healthy adults. Published data indicates that a single administration produced sustained, dose-dependent increases in GH and IGF-1 levels lasting up to 6 days, with IGF-1 increases of 20–40% maintained over multiple weeks of weekly dosing.
The extended half-life of DAC-modified CJC-1295 fundamentally changes the research model — instead of studying pulsatile GH release, researchers are studying sustained elevation of the GH/IGF-1 axis. Both models have distinct scientific value.
Ipamorelin
Ipamorelin is widely regarded by researchers as one of the most selective GHRPs available. Its primary research advantage is selectivity: studies have demonstrated that it stimulates GH release with minimal concurrent elevation of cortisol (a stress hormone) or prolactin (a hormone involved in lactation and immune function) — effects commonly observed with less selective GHRPs like GHRP-6 and hexarelin.
Research by Raun and colleagues (PMID: 9849822), published in European Journal of Endocrinology, characterized ipamorelin's selectivity profile in animal models and confirmed its potent, selective GH-releasing activity with a favorable side-effect profile compared to earlier GHRPs.
Published data indicates that ipamorelin's high selectivity for GHS-R1a, with minimal off-target hormonal activity, makes it a particularly useful research tool when investigators want to isolate GH axis effects from confounding hormonal variables.
GHRP-2 and GHRP-6
GHRP-2 (view product) and GHRP-6 (view product) are first- and second-generation GHRPs respectively, and remain important research compounds because of their well-characterized pharmacology and extensive published literature.
The key research distinction between them:
| Compound | GH Release Potency | Cortisol/Prolactin Effect | Appetite Stimulation | Selectivity |
|---|---|---|---|---|
| GHRP-6 | High | Moderate | Pronounced | Lower |
| GHRP-2 | High | Moderate-High | Mild | Moderate |
| Ipamorelin | Moderate-High | Minimal | Minimal | High |
| Hexarelin | Very High | High | Minimal | Lowest |
Research by Arvat and colleagues (PMID: 9467549), published in European Journal of Endocrinology, characterized GHRP-2's ability to stimulate GH release in human subjects and noted its capacity to partially overcome somatostatin suppression — a mechanistically interesting finding for researchers studying GH axis regulation.
GHRP-6's pronounced appetite-stimulating effect has made it a subject of research interest independent of GH — specifically for studying ghrelin receptor signaling and its relationship to appetite regulation and energy homeostasis.
Hexarelin
Hexarelin is the most potent GHRP by absolute GH-releasing capacity. Research has revealed an intriguing secondary finding: hexarelin also appears to interact with CD36 receptors in cardiac tissue, independent of GH release. Studies have demonstrated cardioprotective effects in animal models through this GHS-R-independent pathway (PMID: 11463730, Muccioli et al., European Journal of Pharmacology). This dual mechanism makes hexarelin an unusually interesting research compound for cardiovascular biology investigations.
The hexarelin-CD36 interaction represents one of the most compelling examples of how peptide research yields unexpected mechanistic insights beyond the compound's primary intended action.
Tesamorelin
Tesamorelin is a synthetic analog of GHRH with a trans-3-hexenoic acid modification at the N-terminus that confers enhanced stability compared to native GHRH. It has one of the most extensive clinical research records in this compound class.
Research has focused particularly on tesamorelin's effects on visceral adipose tissue (VAT) — the metabolically active fat stored around internal organs. A study by Falutz and colleagues (PMID: 17901295), published in the New England Journal of Medicine, examined tesamorelin's effects in HIV-associated lipodystrophy and reported statistically significant reductions in visceral fat. This remains one of the most rigorous published datasets in the GHRH analog space.
MK-677 (Ibutamoren)
MK-677 occupies a unique position in GH secretagogue research as the only orally bioavailable compound in common use. As a non-peptide ghrelin mimetic, it bypasses the stability and bioavailability challenges that affect peptide compounds.
A foundational study by Murphy and colleagues (PMID: 9467542) published in The Journal of Clinical Endocrinology & Metabolism demonstrated that oral MK-677 produced sustained, dose-dependent increases in GH and IGF-1 levels in both younger and older adults, with effects maintained over weeks of daily research dosing. The oral route and prolonged activity period make it a distinctively useful research tool for longitudinal studies of GH axis activity.
Practical Research Information
Solubility and Reconstitution
Most GH peptides in this class are supplied as lyophilized (freeze-dried) powders. Standard reconstitution uses bacteriostatic water (sterile water with 0.9% benzyl alcohol as a preservative) which allows multiple withdrawals from a single vial while maintaining sterility.
| Compound | Common Solvent | Notes |
|---|---|---|
| Sermorelin | Bacteriostatic water | Stable post-reconstitution; refrigerate |
| CJC-1295 (no DAC) | Bacteriostatic water | Use within 20–30 days once reconstituted |
| CJC-1295 (with DAC) | Bacteriostatic water | Extended albumin binding; stable |
| Ipamorelin | Bacteriostatic water | Highly stable; pairs well with GHRH analogs |
| GHRP-2 / GHRP-6 | Bacteriostatic water | Stable; light-sensitive |
| Hexarelin | Bacteriostatic water | Light-sensitive; amber vials recommended |
| Tesamorelin | Sterile water | Follow specific reconstitution guidelines |
| MK-677 | Oral solution/capsule | No reconstitution required |
Storage and Stability
- Lyophilized (unreconstituted) peptides should be stored at -20°C (freezer) for long-term stability, or at 2–8°C (refrigerator) for short-term storage of up to several months.
- Reconstituted peptides should be stored at 2–8°C and used within 20–30 days for most compounds. Avoid repeated freeze-thaw cycles, which degrade peptide structure.
- Light exposure accelerates degradation in many peptides. Store in amber or opaque vials where possible, and minimize light exposure during handling.
- MK-677, as a small molecule, has substantially greater stability and can be stored at room temperature in appropriate formulations.
Peptide degradation is often invisible — there's no color change or precipitation to warn you. Proper storage from the moment of receipt is the single most important quality-control variable within a researcher's direct control.
Research Combinations
The synergistic relationship between GHRH analogs and GHRPs is one of the most consistently replicated findings in this field. For researchers interested in maximizing GH axis stimulation, combination approaches are well-documented in the literature.
A pre-formulated option for researchers is the CJC-1295 + Ipamorelin combination, which pairs a GHRH analog with a selective GHRP in a single vial — a practical option for research protocols where both pathways are being studied simultaneously.
Research Considerations
Choosing the Right Compound for Your Research Question
The diversity of compounds in this class isn't just about potency — each has a distinct pharmacological profile that makes it more or less appropriate depending on the research question.
- For physiologically authentic GH pulse research: Sermorelin or CJC-1295 Without DAC (short half-lives, pulsatile release)
- For sustained GH/IGF-1 elevation studies: CJC-1295 With DAC or MK-677
- For selectivity-controlled GH axis research: Ipamorelin (minimal off-target hormone effects)
- For visceral adiposity and metabolic research: Tesamorelin (strongest published data in this area)
- For cardiovascular receptor biology: Hexarelin (CD36 pathway research)
- For oral bioavailability and longitudinal designs: MK-677
- For appetite/ghrelin signaling research: GHRP-6
Hormonal Context Matters
GH secretagogues don't operate in isolation. Research has demonstrated that somatostatin tone (the degree of natural inhibitory activity), sleep state, nutritional status, and age all significantly influence GHS response magnitude. Researchers designing protocols should account for these variables, as they represent major sources of inter-subject and intra-subject variability in published datasets.
Receptor Desensitization
Research has demonstrated that continuous receptor activation can lead to desensitization — a reduction in receptor responsiveness over time. This is particularly relevant for GHS-R1a agonists. Published data suggests this effect is less pronounced with GHRH analogs, which is one rationale researchers have explored for alternating or cycling research protocols.
Measuring Research Outcomes
When working with GH secretagogues, the relevant measurable endpoints in research models include:
- Serum GH levels (pulsatile; sampling timing matters significantly)
- Serum IGF-1 levels (more stable, integrates GH exposure over time)
- IGFBP-3 (IGF-1 binding protein; rises in parallel with IGF-1)
- Body composition markers (lean mass, fat mass via DEXA in appropriate models)
- Sleep architecture (GH release is closely coupled to slow-wave sleep)
Disclaimer
For research purposes only. Not for human consumption.
All compounds discussed in this article are intended exclusively for use in legitimate scientific research by qualified investigators. None of the information presented here constitutes medical advice, and no compound discussed should be construed as having been approved for human therapeutic use in this context. Research suggests mechanisms of action and published data indicates biological activity; this does not imply safety or efficacy for any clinical application. Researchers are responsible for compliance with all applicable institutional, local, and national regulations governing the use of research compounds. Published study citations are provided for reference and do not constitute endorsement of any specific research protocol.